改良标准型BEACOPP方案治疗进展期霍奇金淋巴瘤的疗效和安全性  

Efficacy and safety of modified baseline BEACOPP regimen in the treatment of advanced Hodgkin's lymphoma

作　　者：林宁晶[1,2,3] 张运涛[1,2,3] 郑文[1,2,3] 王小沛[1,2,3] 宋玉琴[1,2,3] 涂梅峰[1,2,3] 平凌燕 应志涛[1,2,3] 朱军[1,2,3] 

机构地区：[1]北京大学临床肿瘤学院 [2]北京肿瘤医院 [3]北京市肿瘤防治研究所淋巴肿瘤科暨恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《肿瘤》2010年第1期42-47,共6页Tumor

摘　　要：目的:探讨改良标准型BEACOPP方案(博来霉素+依托泊苷+多柔比星+环磷酰胺+长春新碱+甲基苄肼+强的松)治疗进展期霍奇金淋巴瘤的疗效和安全性。方法:22例初治的进展期霍奇金淋巴瘤患者接受改良标准型BEACOPP方案化疗,同时对于初始肿瘤最大径≥5 cm及化疗后有肿瘤病灶残留的患者给予放疗。结果:22例患者中有16例获得完全缓解,5例获得部分缓解,总有效率为95.5%。在各项临床因素中,国际预后评分对能否获得完全缓解有显著影响(P=0.011)。所有患者的1、2和3年总生存率均为95.5%,1、2和3年无进展生存率分别为72.7%、53.1%和53.1%,1、2和3年的无病生存率分别为85.9%、76.4%和76.4%。单因素分析发现,性别、国际预后评分以及能否获得完全缓解对无进展生存的影响有统计学意义(P<0.05)。主要不良反应为骨髓抑制和肝功能损害,其中3例(13.6%)患者出现Ⅲ度药物性肺损伤。治疗期间未观察到治疗相关性死亡。结论:改良标准型BEACOPP方案治疗初治的进展期霍奇金淋巴瘤是有效而安全的。Objective：To investigate the safety and efficacy of a modified baseline BEACOPP regimen（bleomycin＋etoposide＋adriamycin＋cyclophosphamide＋vincristine＋ procarbazine hydrochloride＋ prednisone） in the treatment of advanced Hodgkin ＇s lymphoma（HL）.Methods：From March 2006 to September 2008,22 previously untreated patients with stages Ⅱ（bulky）,Ⅲ and Ⅳ HL were treated with a modified baseline BEACOPP regimen.Each patient was scheduled to receive 6 to 8 cycles of BEACOPP with consolidation radiotherapy to bulky（≥5 cm） or residual disease.Results：There were 11 males and 11 females with a median age of 28 years（15 to 61 years old）.Twelve patients（54.5%） had nodular sclerosis HL,and 10（45.5%） had mixed cellularity HL.There were 4 patients in stageⅡ,7 in stage Ⅲ and 11 in stage Ⅳ.Sixteen patients（72.7%） achieved a complete remission（CR） and 5 patients（22.7%） had partial remission（PR）.The total effective rate（CR＋PR） was 95.5%.Among all kinds of clinical factors International Prognostic Score（IPS） had significant effect on CR rate（P=0.011）.The 1-,2-and 3-year total survival rates were the same（95.5%）;the 1-,2-and 3-year progression-free survival（PFS） rates were 72.7%,53.1% and 53.1%,respectively;the 1-,2-and 3-year disease-free survival rates were 85.9%,76.4% and 76.4%,respectively.Univariate analysis showed that the gender,IPS and whether achieving CR had significant effects on PFS（P0.05）.The main toxic effects were bone marrow depression and liver injury.Three patients（13.6%） had grade Ⅲ drug-induced lung injury.No treatment-related death was observed.Conclusion：The modified baseline BEACOPP regimen was effective and safe for treatment of newly diagnosed patients with advanced HL.

关 键 词：霍奇金病 抗肿瘤联合化疗方案 改良标准型BEACOPP方案 治疗结果 存活率 

分 类 号：R733.42[医药卫生—肿瘤]